drugset
drugset / Trial / NCT05980065

To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects

NCT05980065 ↗

Phase 1 Completed 35 enrolled Seoul National University Hospital Ensol Biosciences, Inc. · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

A dose-block randomized, double-blind, placebo-controlled, single and multiple ascending dose, first-in-human, phase 1 first in human clinical trial to evaluate the safety, tolerability, and pharmacokinetics after subcutaneous administration of C1K in healthy Korean subjects.

Timeline

Start
2022-12-20
Primary completion
2023-06-13
Completion
2023-10-04

Drugs

EvaluationDrugModalityDoseRoute
Subject C1K Unknown 150 mg Subcutaneous
Subject C1K Unknown 300 mg Subcutaneous
Subject C1K Unknown 600 mg Subcutaneous
Subject C1K Unknown 900 mg Subcutaneous
Subject C1K Unknown 1200 mg Subcutaneous

Indications

No indication recorded.